Live Breaking News & Updates on மேம்படுத்தப்பட்டது உலகளாவிய பொது

April 1, 2021
By Bio-IT World Staff
April 1, 2021 | New investment funds for late-stage companies and public health. Next-gen genomic medicines and single-cell multiomics get cash, and PatientsLikeMe raises a new round of funding to expand.
 
$969M Investment Fund for Early to Late-Stage Companies
Foresite Capital, a multi-stage healthcare and life sciences investment firm, has announced its fifth and largest fundraise with $969 million in capital commitments, significantly oversubscribed above its original target. The offering comprises Foresite Capital Fund V, L.P. and Foresite Capital Opportunity Fund V, L.P. With these new funds, Foresite Capital is investing in emerging healthcare and life sciences companies at all stages that are solving some of the biggest inefficiencies and pain points of the $10 trillion global healthcare market. Foresite Capital now has ~$4 billion in assets under management. Press release. ....

New York , United States , Glasgow City , United Kingdom , France General , Al Iskandariyah , North Pond , City Of , World Health Organization , Al Qahirah , Neil Hunt , Matthew Baker , Eyal Gura , Madelyn Trupkin Herzfeld , Hans Peter Kiem , Jeff Leerink , Anne Wojcicki , Ensoma Engenious , Asher Bio , Rory Mcilroy , Dexcel Pharma , George Roberts , Asher Biotherapeutics , Henry Kravis , Macarthur Foundation , Department Of Pure ,